BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stucchi R, Boin I, Angerami R, Zanaga L, Ataide E, Udo E. Is Isoniazid Safe for Liver Transplant Candidates With Latent Tuberculosis? Transplantation Proceedings 2012;44:2406-10. [DOI: 10.1016/j.transproceed.2012.07.035] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Brown MR, Schult RF. Isoniazid. Reference Module in Biomedical Sciences 2022. [DOI: 10.1016/b978-0-12-824315-2.00121-4] [Reference Citation Analysis]
2 Rashid HU, Begum NAS, Kashem TS. Mycobacterial infections in solid organ transplant recipients. Korean J Transplant 2021;35:208-17. [DOI: 10.4285/kjt.21.0033] [Reference Citation Analysis]
3 Lauar ID, Faria LC, Romanelli RMC, Clemente WT. Latent tuberculosis: Risk factors, screening and treatment in liver transplantation recipients from an endemic area. World J Transplant 2021; 11(12): 512-522 [DOI: 10.5500/wjt.v11.i12.512] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Korayem GB, Alissa DA, AlSuhaibani NI, AlSwailem GS, AlShammari MA, Yaqoob I, Aljasser DS, Almaghrabi RS. Empiric vs screening-based use of isoniazid for tuberculosis prophylaxis: Safety and effectiveness in lung transplant recipients in Saudi Arabia. Transpl Infect Dis 2021;23:e13473. [PMID: 32978858 DOI: 10.1111/tid.13473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Abad CL, Razonable RR. Prevention and treatment of tuberculosis in solid organ transplant recipients. Expert Rev Anti Infect Ther 2020;18:63-73. [PMID: 31826668 DOI: 10.1080/14787210.2020.1704255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
6 Coşkun F, Sakarya M, Selimoğlu K, Dündar HZ, Kıyıcı M, İşçimen R, Yesilbursa D, Kaya E. KARACİĞER NAKİL HASTALARINDA LATENT TÜBERKÜLOZ TEDAVİ YAKLAŞIMI: BURSA ULUDAĞ ÜNİVERSİTESİ DENEYİMİ. Uludağ Üniversitesi Tıp Fakültesi Dergisi 2019. [DOI: 10.32708/uutfd.622962] [Reference Citation Analysis]
7 Abad CLR, Deziel PJ, Razonable RR. Treatment of latent TB Infection and the risk of tuberculosis after solid organ transplantation: Comprehensive review. Transpl Infect Dis 2019;21:e13178. [PMID: 31541575 DOI: 10.1111/tid.13178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
8 Philley JV, Griffith DE. Antimycobacterial Consideration in Transplantation Including Drug Non-susceptibility and Resistance: Tuberculosis and Nontuberculous Mycobacterial Disease. Principles and Practice of Transplant Infectious Diseases 2019. [DOI: 10.1007/978-1-4939-9034-4_56] [Reference Citation Analysis]
9 Santoro-Lopes G, Subramanian AK, Molina I, Aguado JM, Rabagliatti R, Len O. Tuberculosis Recommendations for Solid Organ Transplant Recipients and Donors. Transplantation. 2018;102:S60-S65. [PMID: 29381579 DOI: 10.1097/tp.0000000000002014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
10 Sgarabotto D, Fasolato S, Vianello F, Vittadello F, Boccagni P, Ferrarese A, Burra P, Angeli P, Cillo U. Antibiotic prophylaxis for preventing postorthotopic liver transplant tuberculosis: is there a safe alternative to isoniazid? Transpl Int. 2017;30:734-736. [PMID: 28332726 DOI: 10.1111/tri.12955] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
11 Knoll BM, Nog R, Wu Y, Dhand A. Three months of weekly rifapentine plus isoniazid for latent tuberculosis treatment in solid organ transplant candidates. Infection. 2017;45:335-339. [PMID: 28276008 DOI: 10.1007/s15010-017-1004-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
12 Mcculloch M, Lin PL. Globalization of pediatric transplantation: The risk of tuberculosis or not tuberculosis. Pediatr Transplantation 2017;21:e12891. [DOI: 10.1111/petr.12891] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Muñoz L, Santin M. Prevention and Management of Tuberculosis in Transplant Recipients: From Guidelines to Clinical Practice. Transplantation 2016;100:1840-52. [DOI: 10.1097/tp.0000000000001224] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
14 Sandgren A, Vonk Noordegraaf-Schouten M, van Kessel F, Stuurman A, Oordt-Speets A, van der Werf MJ. Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infect Dis 2016;16:204. [PMID: 27184748 DOI: 10.1186/s12879-016-1550-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
15 Machado CM. Transplant Infections in Developing Countries. Transplant Infections 2016. [DOI: 10.1007/978-3-319-28797-3_9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Young JH, Weisdorf DJ. Typical and Atypical Mycobacterium Infections After Hematopoietic Stem Cell or Solid Organ Transplantation. Transplant Infections 2016. [DOI: 10.1007/978-3-319-28797-3_22] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Meije Y, Piersimoni C, Torre-Cisneros J, Dilektasli AG, Aguado JM; ESCMID Study Group of Infection in Compromised Hosts. Mycobacterial infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20 Suppl 7:89-101. [PMID: 24707957 DOI: 10.1111/1469-0691.12641] [Cited by in Crossref: 72] [Cited by in F6Publishing: 77] [Article Influence: 9.0] [Reference Citation Analysis]
18 Grim SA, Layden JE, Roth P, Gallitano S, Adams W, Clark NM. Latent tuberculosis in kidney and liver transplant patients: a review of treatment practices and outcomes. Transpl Infect Dis. 2015;17:768-777. [PMID: 26263530 DOI: 10.1111/tid.12436] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
19 Isoniazid. Reactions Weekly 2014;1496:27-27. [DOI: 10.1007/s40278-014-0103-7] [Reference Citation Analysis]
20 Acquisto N. Isoniazid. Encyclopedia of Toxicology 2014. [DOI: 10.1016/b978-0-12-386454-3.00740-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
21 Stine JG, Lewis JH. Hepatotoxicity of antibiotics: a review and update for the clinician. Clin Liver Dis 2013;17:609-42, ix. [PMID: 24099021 DOI: 10.1016/j.cld.2013.07.008] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]